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Abstract While the prognosis of patients with glioblas-
toma (GBM) remains poor despite recent therapeutic
advances, variable survival times suggest wide variation in
tumor biology and an opportunity for stratiﬁed interven-
tion. We used volumetric analysis and morphometrics to
measure the spatial relationship between subventricular
zone (SVZ) proximity and survival in a cohort of 39 newly
diagnosed GBM patients. We collected T2-weighted and
gadolinium-enhanced T1-weighted magnetic resonance
images (MRI) at pre-operative, post-operative, pre-radia-
tion therapy, and post-radiation therapy time points, mea-
sured tumor volumes and distances to the SVZ, and
collected clinical data. Univariate and multivariate Cox
regression showed that tumors involving the SVZ and
tumor growth rate during radiation therapy were indepen-
dent predictors of shorter progression-free and overall
survival. These results suggest that GBMs in close prox-
imity to the ependymal surface of the ventricles convey a
worse prognosis-an observation that may be useful for
stratifying treatment.
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Introduction
Glioblastoma(GBM),themostfrequentmalignantgliomain
adults [1] conveys a grim outlook, with median overall sur-
vival of 12–14 months from diagnosis. Prognosis and
response to standard therapy with resection, radiation, and
chemotherapy (temozolomide) are highly variable, so it
would be desirable to identify subgroups of patients with
poorer prognosis who may beneﬁt from alternative or more
aggressive chemotherapy and radiation regimens at the time
of diagnosis. Patient age and performance status are long
established clinical prognostic factors in GBM patients [2],
butofthemanymolecularandimagingmarkersinvestigated
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6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation
status are predictive of response to chemoradiation in a ret-
rospectivestudiesandnonehasbeenvalidatedprospectively
[3].Biomarkerspredictiveofprognosisaregreatlyneededto
help individualize therapy of GBM.
Recent papers have suggested that GBM adjacent to the
subventricular zone (SVZ) are more likely to manifest the
highly invasive and multifocal phenotype and may be
associated with increased morbidity [4, 5]. Based on this,
we hypothesized that GBM adjacent to the SVZ may have
worse outcomes. We explored this hypothesis by longitu-
dinally evaluating the size and location of tumors and
correlating these measures with overall and progression-
free survival in a retrospective sample of newly diagnosed
GBM patients.
Patients and methods
Patient population
Our hospital institutional review board approved this study.
Consecutive glioblastoma (GBM, grade IV glioma)
patients conﬁrmed by surgical pathology at our hospital
who presented initially between March 2003 and August
2005 were retrospectively identiﬁed through an institu-
tional database. We identiﬁed 493 patients with diagnosis
of glioma of any type. Of these, 75 patients had patho-
logical diagnosis of GBM. Of these, 36 patients were
excluded due to inadequate imaging or clinical follow-up;
leaving 39 local patients whose pre-operative, post-opera-
tive, pre-radiation therapy and post-radiation therapy MRI
scans could be obtained for analysis. All patients had
undergone resection followed by involved-ﬁeld radiation
therapy (RT) with concurrent temozolomide and adjuvant
temozolomide. Patients were monitored for progression
and survival through February 2008. No patient was treated
with bevacizumab.
Imaging data collection and post-processing
MRI was performed on 1.5 or 3.0 Tesla scanners (GE
Medical Systems, Milwaukee, WI) using standard institu-
tional brain tumor imaging protocols. At a uniform delay
following intravenous administration of 20 cc of gadop-
entate dimeglumine, T1-weighted spin-echo axial images
(GdT1WI) were acquired with TR = 417–550 ms,
TE = 20 ms, slice thickness = 5 mm, and matrix = 256
2
pixels. Fast spin echo (FSE) T2-weighted images (T2WI)
with slice thickness = 5 mm, and matrix = 256
2–512
2
pixels were acquired using either pre-contrast ﬂuid atten-
uated inversion recovery (FLAIR) technique with
TR = 125–133 ms, TE = 8,002 ms, or conventional FSE
technique with TR = 99–102 ms, TE = 4,250–5,300 ms.
Tumor volumes were calculated using manual segmenta-
tion software (ITK-SNAP, Chapel Hill, NC).
Measurements
Tumor volumes and interval growth rates
GdV and T2V (volumes): Volume of abnormal enhance-
ment (GdV) was measured on GdT1WI. Volume of
abnormal T2 prolongation (T2V) was measured from
FLAIR images in 66 scans and conventional FSET2WI in
the 41 scans lacking diagnostic-quality FLAIR images.
DGdV and DT2V (volumetric growth rates): Enhancing
tumor growth rate (DGdV) and non-enhancing tumor
growth rate (DT2V) were calculated between pre-opera-
tive and post-operative and between pre-radiation and
post-radiation scans by subtracting the earlier volume
from the later volume and dividing the resulting change
in volume by the number of days between the two
scans.
Tumor distances from the ventricles
GdED and T2ED (edge distances): Distance from the edge
of the abnormality to the ependyma of the ventricles was
measured on GdT1WI (GdED) and T2WI images (T2ED)
(Fig. 1). If the abnormality extended to the ependymal
surface of the ventricle, this was noted as GdED = 0o r
T2ED = 0.
GdCD and T2CD (center distances): Distance from the
geometric center of abnormality to the ventricle was
measured on GdT1WI (GdCD) or T2WI (T2CD). The
geometric center was deﬁned as the intersection of the
largest in-plane anteroposterior and orthogonal diameters
of contrast enhancement or T2 prolongation on the axial
sections demonstrating the largest area of abnormality on
GdT1WI or T2WI respectively (Fig. 1).
Distances (GdED, GdCD, T2ED, and T2CD) were
measured in millimeters using FDA-approved commercial
clinical DICOM viewing software (GE Centricity, Mil-
waukee WI).
Tumor location
Using the geometric center of enhancement on the pre-
operative GdT1WI, tumors were categorized as anterior
(A) or posterior (P) relative to the central sulcus and left
(L) or right (R) relative to the interhemispheric ﬁssure.
Tumors centered in the temporal lobe were classiﬁed in the
P subgroup.
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When operative notes documented biopsy without attempt
at deﬁnitive resection, the surgery was classiﬁed as a
biopsy. If resection was attempted, the extent of resection
was classiﬁed by analysis of the amount of abnormal
enhancing tissue remaining on the post-operative GdT1WI
using recently published methods [6]: detection of
[10 cm
3 led to classiﬁcation as subtotal resection (STR)
and B1.0 cm
3 as gross total resection (GTR).
Assessment of multifocality
Brain MRI images acquired at initial presentation and last
follow-up and all spine MRI scans were assessed by two
expertreviewers(GY,SK)forevidenceofmultifocalglioma
at presentation and/or cerebrospinal ﬂuid (CSF) spread
during the course of therapy. Tumors having loci of abnor-
mal enhancement separated by more than 2 cm on the initial
pre-operative study were classiﬁed as multifocal [7]. Some
reports have attempted to distinguish between multifocal
glioma,presumedtorepresentearlyspreadofasinglelesion,
and multicentric glioma, presumed to represent lesions that
arose at multiple locations at one time [17]. Because the
distinctionisdifﬁculttomakeinpracticeandrecentanalyses
have demonstrated no difference in time to progression or
survival between these groups [16], we did not attempt to
distinguishbetweentheseputativesubtypes.CSFspreadwas
deﬁned as occurrence of at least one new non-contiguous
locus of abnormal enhancing tumor arising along the epen-
dyma of the ventricles, pia covering the brain or spinal cord,
or elsewhere in the subarachnoid space after the initial
scan [4].
Statistical analysis
Patientsinthestudycohortwerecomparedtothoseexcluded
from analysis with respect to age, Karnofsky performance
Fig. 1 Measurement of T2
volume (T2V; left upper
frame—thick red border),
enhancing volume (GdV; right
upper frame—thick red border),
T2 edge distance (T2ED; left
lower frame—radial yellow line
from tumor edge to ventricle),
enhancing edge distance
(GdED; right lower frame—
radial yellow line from tumor
edge to ventricle), T2 center
distance (T2CD; left upper and
lower frames—green line from
centroid to ventricle), and
enhancing center distance
(GdCD; right upper and lower
frames—left upper and lower
frames—green line from
centroid to ventricle) for
patients with T2ED = 0 and
GdED = 0 (upper) and
T2ED[0 and GdED[0.
(Color ﬁgure online)
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123status (KPS), and sex by t-test, Wilcoxon rank sum test, and
Fisher’s exact test, respectively. Overall survival (OS) and
progression-free survival (PFS) were calculated in months
from the pre-operative MRI. Progression was deﬁned using
Macdonald criteria [8]. The OS and PFS curves and median
survival times were calculated as Kaplan–Meier product-
limit estimates. Associations between OS and PFS and the
following independent variables were analyzed by logrank
testandunivariateandmultivariateCoxregression:age,sex,
KPS, tumor location, duration of radiationtherapy, extentof
surgical resection, multifocality, CSF spread, GdV, T2V,
DGdV, DT2V, GdCD, T2CD, GdED, and T2ED. The uni-
variate analyses were considered exploratory. Reported P-
values were not corrected for multiple comparisons. Multi-
variate models were identiﬁed by best subset selection with
modelcomplexitychosenbyBayesianinformationcriterion.
Terms for age (both constant and time-dependent) and other
previously identiﬁed predictors of outcome (extent of
resection, multifocality, CSF spread, and pre-operative
tumor volume) were includedinall models.Optimal models
constructed from baseline predictors were selected prior to
incorporating measures assessed after baseline. Due to our
model selection procedure, the nominal P-values may be
lowerthanwouldbeestimatedfromanindependentdataset.
Results
Patient population, tumor characteristics, and survival
The study cohort included 29 male and 10 female patients.
Mean age was 58 years (range: 27–81), median KPS 70, and
median follow-up time 18.2 months (range, 3.1–41.7).
Nineteen patients (49%) had posterior tumors, including 7
temporal lobe tumors (37% of the P subgroup, 18% overall).
Thirty-three patients (85%) underwent biopsy and 6 patients
(15%) STR. Four patients (10%) had multifocal tumor at
presentation. CSF spread was detected during follow-up in 4
patients(10%).Onthepre-operativescan,signalabnormality
extended to the ependyma of the ventricles on T2WI
(T2ED = 0) in 30/39 patients (77%) and on GdT1WI
(GdED = 0)in16/39patients(41%)(Table 1).Fourpatients
werealive atthe end offollow-up. Medianpost-operativeOS
was 15.6 months (95% CI: 11.1–24.1, Fig. 2) and median
post-operativePFS6.7 months(95%CI:5.2–7.2,Fig. 3).The
36 patients who were excluded had similar baseline features:
age (median = 54 years, P = 0.12), KPS (median = 70,
P = 0.67), and sex (male = 64%, P = 0.45).
Overall survival analysis
Univariate Cox regression identiﬁed older patient age and
lower KPS as signiﬁcant predictors of poor overall
Table 1 Patient and tumor characteristics (n = 39)
Variable Summary
(mean ± SD [range] or n [%])
Age (years) 58.4 ± 11.9 (27.7, 81.8)
KPS 74.4 ± 10.5 (60, 100)
Gender (male) 29 (74%)
Brain region (posterior) 19 (49%)
Hemisphere (left) 19 (49%)
Resection extent (biopsy) 33 (85%)
Multifocal at diagnosis 4 (10%)
CSF dissemination 4 (10%)
RT duration (months) 2.74 ± 0.54 (1.97, 4.93)
Pre-Op T2V (mm
3) 113 ± 62 (5.36, 241)
Pre-Op GdV (mm
3) 35.7 ± 25.8 (0.106)
2
Pre-RT T2V (mm
3) 108 ± 62 (12.6, 260)
Pre-RT GdV (mm
3) 41.2 ± 27.8 (4.10, 117)
Post-RT T2V (mm
3) 126 ± 102 (0.711, 437)
Post-RT GdV (mm
3) 32.0 ± 24.8 (0.550, 101)
a
Pre-Op T2ED (mm) 2.29 ± 5.71 (0.27.1)
Pre-Op GdED (mm) 7.27 ± 10.5 (0.41.4)
Pre-RT T2ED (mm) 1.80 ± 4.71 (0.24.8)
Pre-RT GdED (mm) 6.15 ± 8.52 (0.26.5)
Post-RT T2ED (mm) 0.701 ± 2.32 (0.11.4)
Post-RT GdED (mm) 5.41 ± 7.72 (0.26.6)
Pre-Op T2ED = 0 (yes vs. no) 30 (77%)
Pre-Op GdED = 0 (yes vs. no) 16 (41%)
Pre-RT T2ED = 0 (yes vs. no) 30 (77%)
Pre-RT GdED = 0 (yes vs. no) 15 (39%)
Post-RT T2ED = 0 (yes vs. no) 35 (90%)
Post-RT GdED = 0 (yes vs. no) 16 (41%)
Pre-Op T2CD (mm) 20.7 ± 8.0 (9.58, 37.8)
Pre-Op GdCD (mm) 28.2 ± 11.0 (8.76, 50.5)
Pre-RT T2CD (mm) 22.5 ± 10.5 (3.39, 48.8)
Pre-RT GdCD (mm) 26.8 ± 11.3 (9.33, 55.5)
Post-RT T2CD (mm) 17.8 ± 7.7 (3.92, 31.8)
Post-RT GdCD (mm) 24.3 ± 10.5 (8.90, 50.1)
Pre-Op?Pre-RT DT2V (mm
3/day) –1.45 ± 4.92 (–16.0, 12.6)
Pre-Op?Pre-RT DGdV (mm
3/day) –0.215 ± 5.21 (–16.8, 17.5)
Pre?Post-RT DT2V (mm
3/day) 0.216 ± 1.01 (–0.940, 3.07)
Pre?Post-RT DGdV (mm
3/day) –0.100 ± 0.271 (–0.843, 0.613)
a GdV data at the early and post-RT time points are based on 38 of 39
patients because T1WI scans were incompatible with the segmentation
software
Pre-Op before biopsy or resection, Pre-RT after surgery and before
radiation therapy, Post-RT after radiation therapy, T2V volume of abnor-
mal T2 prolongation on FLAIR/FSE T2WI, GdV volume of the tumor on
GdT1WI, T2ED distance from the edge of the abnormality to the ventri-
cles on FLAIR/FSE T2WI images, GdED distance from the edge of the
abnormality to the ventricles on GdT1WI, T2CD distance from the center
of the tumor to the ventricles on FLAIR/FSE T2WI, GdCD distance from
the center of the tumor to the ventricles on GdT1WI, DT2V the difference
in volume divided by the number of days between FLAIR/FSE T2WI
scans, DGdV the difference in volume divided by the number of days
between GdT1WI scans, T2ED = 0 signal abnormality extended to the
ventricle on FLAIR/FSE T2WI, GdED = 0 signal abnormality extended
to the ventricle on GdT1WI
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123survival, with a 44% increase in mortality hazard for each
10-year increment in age and a 40% increase in mortality
hazard for each 10-unit decrease in KPS. Controlling for
age and KPS, increased mortality hazard was associated
with larger post-RT T2V, DT2VC0 over the course of RT,
and tumor abutting the SVZ (GdED = 0) (Supplementary
Table 1).
Multivariate analysis of OS identiﬁed the known poor
prognostic indicators of older age, lower KPS, and smaller
extent of surgical resection as independent predictors of
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Fig. 2 Kaplan–Meyer plots depicting overall survival of the full
cohort (a) and stratiﬁed by age (b), KPS (c), pre-operative SVZ
involvement (GdED = 0)( d), pre-operative geometric center
distance (GdCD)( e), and change in enhancing tumor growth rate
(DGdV) during radiation therapy (f). P-values from logrank tests
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123increased mortality risk. Older patients were at higher risk
of mortality initially, but analysis of time-dependent effect
of age suggested that younger patients experienced accel-
erated risk of mortality relative to older patients during
follow-up. Controlling for age and KPS, larger pre-opera-
tive GdCD, larger positive DT2V over the course of RT,
and pre-operative GdED = 0 were independent predictors
of mortality risk (Table 2). Pre-operative SVZ involvement
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Fig. 3 Kaplan–Meyer plots depicting progression-free survival of the
full cohort (a) and stratiﬁed by age (b), KPS (c), pre-operative SVZ
involvement (GdED = 0)( d), pre-operative geometric center
distance (GdCD)( e), and enhancing tumor growth rate (DGdV)
during radiation therapy (f). P-values from logrank tests
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123(GdED = 0) conveyed a nearly fourfold higher risk of
mortality (hazard ratio: 3.70, 95% CI: 1.41–9.73,
P = 0.008) after adjustment for all other predictors of
mortality risk. While the model controlled for pre-opera-
tive GdV and T2V, multifocal presentation, and CSF dis-
semination, these factors were not signiﬁcant independent
predictors of mortality risk. Inference was unchanged and
point estimates changed by less than 2% when CSF dis-
semination and multifocality were dropped from the model.
Progression-free survival analysis
In the univariate analysis, age was not a signiﬁcant pre-
dictor of PFS, but as with OS, a 10-unit decrease in KPS
was associated with a 40% increase in hazard of progres-
sion or death. Larger pre-operative T2CD, larger pre-RT
T2CD and GdCD, larger post-RT T2V and GdV, DT2VC0
over the course of RT, and pre-operative GdED = 0 were
associated with greater hazard of progression or death
(Supplementary Table 1). After controlling for age and
KPS, only larger pre-operative and pre-RT T2CD, and
DT2VC0 over the course of RT, remained signiﬁcant
independent predictors of increased hazard of progression
or death (Supplementary Table 1).
Age, KPS, and extent of surgical resection were not
signiﬁcant predictors of PFS in multivariate analysis.
Larger pre-operative GdCD, DT2VC0 over the course of
RT, and pre-operative GdED = 0 were identiﬁed as inde-
pendent predictors of risk of progression or mortality
(Table 2). GdV prior to surgery, CSF dissemination, and
multifocality were not found to be signiﬁcant predictors of
PFS. Pre-operative GdED = 0 conveyed more than a
fourfold higher risk of tumor progression or mortality
(hazard ratio: 4.24, 95% CI: 1.47–12.2, P = 0.008) after
adjustment for other predictors of progression and mor-
tality risk. Inference was unchanged and point estimates
changed by less than 5% when CSF dissemination and
multifocality were dropped from the model.
Discussion
We have hypothesized that GBM in close proximity to the
SVZ might be more malignant and invasive than GBM
elsewhere. Our retrospective analysis is clearly not able to
establish the origin of these GBM, but does argue for tumor
proximity to the SVZ as an independent predictor for
survival by demonstrating a worse prognosis in patients
whose tumors extend to the ependymal surface of the
ventricles on GdT1WI (GdED = 0). The single previous
report suggesting shorter survival in patients with GBM
adjacent to the lateral ventricles was signiﬁcantly limited
by the heterogeneous extent of resection (35% GTR) and
application of optimal chemotherapy (27% temozolomide)
[9]. In contrast, the absence of GTR, and use of optimal
chemotherapy in all patients in our cohort and the explicit
statistical analysis for the confounding effect of STR ver-
sus biopsy described above make it very unlikely that the
decreased survival of patients with periventricular tumors
in this study was an artifact of incomplete surgical resec-
tion or suboptimal chemotherapy in patients with deeper
tumors.
After controlling for the known prognostic variables of
age, KPS, and extent of surgical resection, univariate
analysis of OS, multivariate analysis of OS, and multi-
variate analysis of PFS all demonstrated increased risk of
progression and mortality in our cohort for tumors having
GdED = 0 at presentation. Univariate analysis of the same
association with PFS was not statistically signiﬁcant at
P = 0.065. This reason that GBM adjacent to the ventri-
cles on the initial GdT1WI conveys a poorer prognosis is
not known. Others and we have hypothesized that more-
Table 2 Multivariate Cox models of overall and progression-free survival
Variable Overall survival Progression-free survival
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (per 10-year increment) 3.15 (1.33, 7.46) 0.009 1.30 (0.67, 2.55) 0.44
Age (time-dependent, per month 9 10 years) 0.42 (0.22, 0.82) 0.010 0.51 (0.23, 1.13) 0.098
KPS (per 10-unit increase) 0.50 (0.28, 0.91) 0.022 0.56 (0.30, 1.04) 0.067
Resection extent (biopsy vs. subtotal) 5.89 (1.39, 25.1) 0.016 2.55 (0.64, 10.2) 0.19
CSF dissemination (yes vs. no) 0.96 (0.23, 4.02) 0.95 1.27 (0.37, 4.33) 0.70
Multifocal at diagnosis (yes vs. no) 0.92 (0.29, 2.92) 0.89 0.79 (0.25, 2.47) 0.69
Pre-Op GdV (per 25 mm
3) 1.18 (0.78, 1.80) 0.44 0.74 (0.41, 1.31) 0.30
Pre-Op GdED = 0 (yes vs. no) 3.70 (1.41, 9.73) 0.008 4.24 (1.47, 12.2) 0.008
Pre-Op GdCD (per 5 mm) 1.21 (1.01, 1.45) 0.040 1.47 (1.21, 1.78) \0.0001
Pre?Post-RT DT2V (per 0.5 mm
3/day) 1.38 (1.11, 1.73) 0.004 1.39 (1.11, 1.75) 0.004
Note abbreviations in Table 1
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123aggressive GBM may arise in the SVZ, potentially from
less differentiated progenitor or stem cells. While more
patients had tumors extending to the ependymal surface of
the ventricles on the T2WI (T2ED = 0) than on the
GdT1WI (GdED = 0), OS and PFS were only associated
with GdED = 0. This seems likely to reﬂect the fact that
abnormality on T2WI represents a variable admixture of
vasogenic edema and non-enhancing tumor whereas
abnormality on GdT1WI may correlate more closely with
the site of origin of the glioma.
Our analysis of confounding factors associated with
deep tumors considered other possible effects, including
greater difﬁculty of resection, greater involvement of deep
white matter, and more common CSF spread. While no
patient in our cohort underwent GTR, biopsy was associ-
ated with a two to six fold increase in risk of progression
or mortality relative to STR. Nevertheless, after controlling
for this variable, the presence of tumor adjacent to the
ventricle on pre-operative GdT1WI images was indepen-
dently predictive of worse OS and PFS. Patients with
inoperable tumors of the brainstem, corpus callosum, left
parietal lobe, and deep nuclei have been reported to have a
poorer overall survival [2, 6, 10], but no such tumors were
observed in our cohort. Recent literature suggests that CSF
spread has no signiﬁcant effect on survival when compared
to local tumor recurrence, but that multifocal enhancing
tumor at presentation decreases survival signiﬁcantly [4,
5]. The percentage of patients in our cohort with CSF
spread and multifocality was similar to those reports.
Although small sample size limits our power to detect
these associations, neither factor predicted signiﬁcantly
shorter OS or PFS in our sample. Thus it seems unlikely
that the association of tumor location in the SVZ with
worse prognosis is an artifact of limited resection,
involvement of deep white matter tracts, multifocality, or
CSF spread. An additional factor that might confound the
study is tumor genetics, which was beyond the scope of the
current study.
In addition to the strong association with extension to
the SVZ, larger pre-op GdCD and pre-RT T2CD were
associated with increased risk of progression and mortality.
Since the ventricle itself blocks medial spread, enlargement
and white matter spread of tumors arising in the SVZ, will
both necessarily displace the geometric center of tumor
farther from the ventricle. Thus, T2CD and GdCD seem
likely to represent surrogate markers for tumor size and/or
extent of white matter spread. Although direct measures of
larger tumor volume were associated with greater risk of
mortality, the association disappeared after controlling for
age, tumor growth rate, and GdED = 0. Because an effect
of tumor size on prognosis is suggested by recent [11, 12]
but not older reports [10, 13], and our sample size is too
small to allow a deﬁnitive conclusion, additional study is
indicated to determine whether tumor size affects progno-
sis after controlling for tumor location in the SVZ.
In addition to acting as a surrogate for larger tumor size,
greater pre-op and pre-RT GdCD and T2CD may reﬂect a
more invasive phenotype. It seems likely that invasiveness
of GBM at baseline and/or success of chemoradiation in
controlling invasiveness may have a strong effect on sur-
vival. Although our study was not designed or powered to
assess this hypothesis, we observed several associations
consistent with this. Both univariate and multivariate
analyses detected a signiﬁcant association of tumor spread
during TMZ/RT (DT2VC0) with decreased survival.
Similarly, univariate analysis revealed that the extent of
abnormality on T2WI after RT (T2V) was a signiﬁcant
predictor of decreased survival. Thus the possibility that
change in extent of FLAIR/FSE T2WI abnormality during
chemoradiation may be a useful surrogate for control of the
inﬁltrative component of GBM. The possible inﬂuence of
this marker on survival deserves further study. In this
context, the fact that GdT1WI measurements of tumor
growth during TMZ/RT and tumor size after RT were not
signiﬁcantly associated with survival, after adjusting for
age and KPS, may reﬂect the greater efﬁcacy of surgery
and chemoradiation at controlling the enhancing focal
component of GBM than the inﬁltrative component.
Analysis in larger data sets including more sophisticated
diffusion weighted imaging derived measures of white
matter invasion, seems indicated to better resolve the
independent effects of tumor volume, inﬁltrative tumor
spread, and SVZ location at presentation.
Limitations of our study include the small sample size
and our inability to control for molecular and genetic
heterogeneity within GBM (including in particular MGMT
methylation status), variability in post-progression salvage
treatments, and longitudinal steroid dosing. Nonetheless,
our ﬁndings illustrate that in addition to being a powerful
research tool, quantitative imaging metrics characterizing
tumor location and inﬁltrative spread of non-enhancing
tumor deserve to be evaluated for stratifying patients for
clinical trials and clinical care.
Our results suggest that patients with GBM extending to
the SVZ, as deﬁned by GdED = 0 on the initial MRI,
should be regarded as having an especially poor prognosis.
After controlling for other known potential negative fac-
tors, tumors touching the SVZ continued to convey a worse
prognosis. Neuropathologists have long postulated that
certain types of GBM arise primarily from the SVZ [14,
15]. Recent characterization of the oncogenic potential of
SVZ stem cells has led to renewed interest in establishing a
correlation between human glioma and the SVZ [16, 17].
Our series certainly does not establish this causative rela-
tionship, but is thought provoking in that we have found
patients with GBM abutting the ventricles to have
268 J Neurooncol (2011) 104:261–269
123outcomes inferior to those whose tumors are some distance
from the SVZ. This negative effect appears to be inde-
pendent of other known factors inﬂuencing outcomes,
though again genetic/epigenetic analysis, differences in
vascularity, and other unknown factors were not evaluated
in this series. As a ﬁrst step, a prospective trial incorpo-
rating focal radiation of the SVZ could be considered
within the sub-population of GBM patients whose tumor
extends to the ependymal surface of the ventricles.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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medium, provided the original author(s) and source are credited.
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